Shire and GalxoSmithKline have teamed up to promote Shire’s ADHD treatment Vyvanse to adults. The combined 1,200-person sales force will cover pediatricians and neuro-health physicians in an effort to reach as large a swathe of specialties as possible. 

This is a huge sales force to focus on a market that is virtually untapped.  The drug has already been approved for years and it doesn't have the bad press that Adderall and Ritalin have.

Vyvanse was initially approved for 6 to 12 year olds but in July of last year it was approved for over 17 and Adults with ADD.

Adderall, which has been facing increased competition from generic brands, was not actively marketed or advertised last year.   This was in preperation for this new drug.  

It differs from Adderall because it's not time released so it should work better for a busy ADD adult.